Almost two-thirds

Featured in: Favicon

investing.com Favicon

politico.eu Favicon

haaretz.com Favicon

talkingpointsmemo.com Favicon

informa.com (+1) Favicon

fabricatingandmetalworking.com Favicon

publicsquaremag.org

Articles

Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving

Oct 15, 2024 | insights.citeline.com | Anju Ghangurde |Almost two-thirds

Biocon: Slow Humira Biosimilar Uptake But Payer Landscape EvolvingBiocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet. Biocon talks about evolving payer dynamics for Humira biosimilar • Source: Shutterstock
Senderra Rolls Out Five Humira Biosimilars Across Its Network

Oct 15, 2024 | insights.citeline.com | Chloe Kent |Almost two-thirds

Senderra Rolls Out Five Humira Biosimilars Across Its NetworkFirm Committed To Making Future Biosimilar Launches AvailableSenderra Specialty Pharmacy is the latest service provider to announce expanding access to adalimumab products, making five Humira biosimilars available across its network.
Amgen Lines Up Biosimilar Launches For Early 2025

Aug 7, 2024 | generics.citeline.com | Almost two-thirds |David Wallace

Analysis Executive Summary Amgen has pointed to two key biosimilar launches in the first quarter of 2025, as it provided updates on its biosimilars business while reporting second-quarter results. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to Generics Bulletin? Request a free trial today!
Draft Biosimilar Red Tape Elimination Act: Pharmacist As Ally, Would Patients Benefit?

Aug 25, 2023 | scrip.pharmaintelligence.informa.com | Almost two-thirds |Vibha Ravi

Analysis Executive Summary If the bill on the Biosimilar Red Tape Elimination Act is passed, all biosimilars would be deemed interchangeable on US FDA approval. Scrip takes a look at what empowering pharmacists could mean, what the generics substitution experience shows and where possible pain points lie You may also be interested in... Existing Subscriber? Sign in to continue reading. New to Scrip? Start a free trial today!
US Amjevita Sales Slide By Almost Two-Thirds

Aug 4, 2023 | generics.pharmaintelligence.informa.com | Almost two-thirds |David Wallace

Amgen’s Humira Biosimilar Turnover Slides In US Ahead Of Fresh Wave Of Launches 04 Aug 2023 Analysis Executive Summary Amgen has revealed a significant – albeit expected – drop in second-quarter sales figures for its Amjevita US biosimilar rival to Humira. You may also be interested in...